Advertisement

Advertisement
Breast Cancer

Phase III postMONARCH Trial: Switching to Abemaciclib May Improve Outcomes After Disease Progression

For hormone receptor–positive, HER2-negative advanced breast cancer that has progressed on CDK4/6 inhibition plus endocrine therapy, the CDK4/6 inhibitor abemaciclib plus fulvestrant significantly reduced the risk of further disease progression in the phase III postMONARCH study.

Skin Cancer

RELATIVITY-048: Triplet Immunotherapy Shows Activity in Untreated Advanced Melanoma

As a first-line treatment of advanced melanoma, the triplet immunotherapy regimen of nivolumab, relatlimab-rmbw, and ipilimumab produced high response rates and promising progression-free and overall survival in the nonrandomized phase I/II RELATIVITY-048 trial, as reported by Paolo Antonio Ascierto, MD, of the Istituto Nazionale dei Tumori IRCCS in Naples, Italy, at the 2024 ASCO Annual Meeting.

Prostate Cancer

MAST Trial: Metformin Does Not Slow Disease Progression of Low-Risk Prostate Cancer

The hypoglycemic agent metformin failed to slow disease progression in men with low-risk localized prostate cancer undergoing active surveillance, according to the results of the randomized, controlled MAST trial reported at the 2024 ASCO Annual Meeting. In addition, the use of metformin was associated with increased gastrointestinal side effects and fatigue.


Advertisement
Leukemia
Myelodysplastic Syndromes

Chronic Graft-vs-Host Disease: Clinical Trial Updates

Chronic graft-vs-host disease, an immune-mediated disorder that follows allogeneic hematopoietic cell transplantation (allo-HCT), is characterized by debilitating tissue injury with inflammatory and fibrotic pathology leading to significant morbidity and mortality. Historically, the treatment of chronic graft-vs-host disease involved broad, systemic immunosuppression, mainly with corticosteroids. As our understanding of the immune and cellular processes underlying chronic graft-vs-host disease has improved, more focused therapies have emerged.

 

Lung Cancer

Second-Line Therapy With Adagrasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer

Second-line therapy with the KRAS inhibitor adagrasib modestly improved progression-free survival and objective response rate over docetaxel in previously treated patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to the primary analysis of the phase III KRYSTAL-12 trial, presented at the 2024 ASCO Annual Meeting. Results also showed more than a doubling of intracranial response among the adagrasib-treated patients compared with those given the standard-of-care docetaxel.

Advertisement
Advertisement





More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Breast Cancer

Capivasertib With Fulvestrant for Previously Treated Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer

On November 16, 2023, capivasertib (Truqap) was approved for use with fulvestrant for patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations, following disease progression on at least one endocrine-based...

Advertisement

Can GLP-1 Receptor Agonists Prevent Obesity-Associated Cancers in Patients With Type 2 Diabetes?

Based on the results of a retrospective U.S. population–based cohort study, which were reported in JAMA Network Open by Wang et al, treatment with glucagon-like peptide 1 (GLP-1) receptor agonists vs insulins seemed to be associated with a decreased risk of developing specific obesity-associated...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Supportive Care
Issues in Oncology

Breaking the Silence: Addressing Sexual and Reproductive Health in Cancer Care

For patients with cancer and cancer survivors, sexual dysfunction and reproductive health concerns are often the elephant in the exam room—a significant quality-of-life issue that both patients and clinicians struggle to discuss openly and effectively. At the recent NCCN Policy Summit on Sexual and ...

Leukemia

Having Acute Lymphoblastic Leukemia Took Away My Fear of Death

On May 30, 2017, 9 days before I turned 19 and soon after I had completed my sophomore year at college, I was diagnosed with aggressive acute lymphoblastic leukemia. But getting to the diagnosis was a tortuous process. I had been feeling fatigued and losing weight for several weeks prior to the...

Resected Pancreatic Cancer: Autologous Dendritic Cell Vaccination

In a Dutch single-center phase I/II study reported in the Journal of Clinical Oncology, van ‘t Land et al found that adjuvant autologous dendritic cell vaccination was associated with promising recurrence-free survival in patients who had undergone resection and standard-of-care treatments for...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Hematologic Malignancies
Supportive Care

Chronic Graft-vs-Host Disease: Clinical Trial Updates

Chronic graft-vs-host disease, an immune-mediated disorder that follows allogeneic hematopoietic cell transplantation (allo-HCT), is characterized by debilitating tissue injury with inflammatory and fibrotic pathology leading to significant morbidity and mortality. Historically, the treatment of...

Advertisement

Association of Genetic Risk for Prostate Cancer With Early Prostate Cancer Death

In a study reported in JAMA Network Open, Plym et al found that men at a higher genetic risk for prostate cancer were more likely to experience early death from prostate cancer compared to men with a lower genetic risk for the disease. Study Details The cohort study used a combined analysis of...

ASCO Post X Feed
Social Media Hub by Everwall